Company’s 36-month beta value is 1.71.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for STRO is 78.04M, and currently, short sellers hold a 8.79% ratio of that floaft. The average trading volume of STRO on June 06, 2025 was 1.86M shares.
STRO) stock’s latest price update
Sutro Biopharma Inc (NASDAQ: STRO)’s stock price has plunge by -9.36relation to previous closing price of 0.91. Nevertheless, the company has seen a -8.41% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-05-08 that Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
STRO’s Market Performance
Sutro Biopharma Inc (STRO) has experienced a -8.41% fall in stock performance for the past week, with a -13.24% drop in the past month, and a -43.93% drop in the past quarter. The volatility ratio for the week is 5.16%, and the volatility levels for the past 30 days are at 6.60% for STRO. The simple moving average for the past 20 days is -6.79% for STRO’s stock, with a -63.70% simple moving average for the past 200 days.
Analysts’ Opinion of STRO
Wedbush, on the other hand, stated in their research note that they expect to see STRO reach a price target of $2, previously predicting the price at $8. The rating they have provided for STRO stocks is “Neutral” according to the report published on March 14th, 2025.
STRO Trading at 1.26% from the 50-Day Moving Average
After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.06% of loss for the given period.
Stock Fundamentals for STRO
Current profitability levels for the company are sitting at:
- -3.77 for the present operating margin
- 0.04 for the gross margin
The net margin for Sutro Biopharma Inc stands at -3.69. The total capital return value is set at -1.33. Equity return is now at value -679.15, with -67.66 for asset returns.
Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated -4.85 points at debt to capital in total, while cash flow to debt ratio is standing at -9.1. The debt to equity ratio resting at -0.83. The interest coverage ratio of the stock is -6.9.
Currently, EBITDA for the company is -180.45 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of -0.23. The receivables turnover for the company is 4.9for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In a nutshell, Sutro Biopharma Inc (STRO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
